Several factors may contribute to dizziness in patients taking GLP-1 medications: Hypoglycaemia (low blood glucose) particularly when GLP-1 agonists are used alongside other glucose-lowering medications such as sulphonylureas or insulin Dehydration resulting from reduced fluid intake due to decreased appetite or from gastrointestinal side effects such as nausea, vomiting, or diarrhoea Orthostatic hypotension a drop in blood pressure upon standing, which may occur due to volume depletion or rapid weight loss Reduced caloric intake significant appetite suppression may lead to inadequate nutrition, potentially causing weakness and dizziness The frequency and severity of dizziness vary between individuals and specific GLP-1 products
Retatrutide has progressed into Phase 3 programs targeting obesity (with and without diabetes), focusing on durability of weight loss, cardiometabolic outcomes, and broader population validation
This was presented at the American Diabetes Association meeting and suggests that mazdutide, through its glucagon receptor activation, drives significant hepatic fat reduction
Weight loss compounds present a fundamental problem: they typically require much larger doses to be effective than can realistically be delivered through the skin
"The field is also exploring migraine, intracranial hypertension, inflammatory bowel disease, psoriasis, and rheumatoid arthritis, all out of my wheelhouse," he says
Liraglutide, exenatide v dapagliflozin tc dng ko di u c ph duyt trong lnh vc bnh tim mch
